Management of Fracture Risk in Patients with Chronic Obstructive Pulmonary Disease (COPD): Building a UK Consensus Through Healthcare Professional and Patient Engagement

Introduction Osteoporosis and bone fractures are common in chronic obstructive pulmonary disease (COPD) and contribute significantly to morbidity and mortality. Current national guidance on COPD management recommends addressing bone health in patients, however, does not detail how. This consensus outlines key elements of a structured approach to managing bone health and fracture risk in patients with COPD. Methods A systematic approach incorporating multifaceted methodologies included detailed patient and healthcare professional (HCP) surveys followed by a roundtable meeting to reach a consensus on what a pathway would look like. Results The surveys revealed that fracture risk was not always assessed despite being recognised as an important aspect of COPD management by HCPs. The majority of the patients also stated they would be receptive to discussing treatment options if found to be at risk of osteoporotic fractures. Limited time and resource allocation were identified as barriers to addressing bone health during consultations. The consensus from the roundtable meeting was that a proactive systematic approach to assessing bone health should be adopted. This should involve using fracture risk assessment tools to identify individuals at risk, investigating secondary causes of osteoporosis if a diagnosis is made and reinforcing non-pharmacological and preventative measures such as smoking cessation, keeping active and pharmacological management of osteoporosis and medicines management of corticosteroid use. Practically, prioritising patients with important additional risk factors, such as previous fragility fractures, older age and long-term oral corticosteroid use for an assessment, was felt required. Conclusion There is a need for integrating fracture risk assessment into the COPD pathway. Developing a systematic and holistic approach to addressing bone health is key to achieving this. In tandem, opportunities to disseminate the information and educational resources are also required.

[1]  T. McKeever,et al.  Predicting fracture risk in patients with chronic obstructive pulmonary disease: a UK-based population-based cohort study , 2019, BMJ Open.

[2]  M. Steiner,et al.  Prospective risk of osteoporotic fractures in patients with advanced chronic obstructive pulmonary disease , 2018, Chronic respiratory disease.

[3]  T. McKeever,et al.  Hip fracture outcomes in patients with chronic obstructive pulmonary disease. , 2018, British journal of anaesthesia.

[4]  T. McKeever,et al.  Risk of fall in patients with COPD , 2018, Thorax.

[5]  K. Park,et al.  Education and exercise program improves osteoporosis knowledge and changes calcium and vitamin D dietary intake in community dwelling elderly , 2017, BMC Public Health.

[6]  T. Greulich,et al.  Prevalence of comorbidities in COPD patients by disease severity in a German population. , 2017, Respiratory medicine.

[7]  C. Cooper,et al.  UK clinical guideline for the prevention and treatment of osteoporosis , 2017, Archives of Osteoporosis.

[8]  E. Segal,et al.  Managing Osteoporosis: A Survey of Knowledge, Attitudes and Practices among Primary Care Physicians in Israel , 2016, PloS one.

[9]  R. Okazaki [COPD and bone]. , 2016, Clinical calcium.

[10]  Piet Geusens,et al.  Epidemiology of fractures in the United Kingdom 1988-2012: Variation with age, sex, geography, ethnicity and socioeconomic status. , 2016, Bone.

[11]  Edwin K Silverman,et al.  Reduced Bone Density and Vertebral Fractures in Smokers. Men and COPD Patients at Increased Risk. , 2015, Annals of the American Thoracic Society.

[12]  P. Geusens,et al.  Fracture prevention in COPD patients; a clinical 5-step approach , 2015, Respiratory Research.

[13]  J. Hallas,et al.  Gastro‐esophageal reflux disease and exacerbations in chronic obstructive pulmonary disease , 2015, Respirology.

[14]  Jasmine Khatana,et al.  Osteoporosis in Chronic Obstructive Pulmonary Disease , 2015, Clinical medicine insights. Circulatory, respiratory and pulmonary medicine.

[15]  T. Coughlan,et al.  Osteoporosis and fracture risk in older people. , 2014, Clinical medicine.

[16]  C. Cooper,et al.  Osteoporosis in the European Union: a compendium of country-specific reports , 2013, Archives of Osteoporosis.

[17]  L. Edwards,et al.  Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort. , 2013, Respiratory medicine.

[18]  W. Henderson,et al.  Improving Hip Fractures Outcomes for COPD Patients , 2013, COPD.

[19]  Sarah E Lamb,et al.  Interventions for preventing falls in older people living in the community. , 2012, The Cochrane database of systematic reviews.

[20]  E. Wouters,et al.  Risk factors for osteoporosis in Caucasian patients with moderate chronic obstructive pulmonary disease: a case control study. , 2012, Bone.

[21]  C. Cooper,et al.  An appendix to the 2012 IOF–ECTS guidelines for the management of glucocorticoid-induced osteoporosis , 2012, Archives of Osteoporosis.

[22]  C. Cooper,et al.  A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis , 2012, Osteoporosis International.

[23]  A. LaCroix,et al.  Burden of non-hip, non-vertebral fractures on quality of life in postmenopausal women , 2012, Osteoporosis International.

[24]  M. Schapira,et al.  The importance of physicians' risk perception in osteoporosis treatment decision making. , 2012, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

[25]  Z. Janovská Bisphosphonate-related osteonecrosis of the jaws. A severe side effect of bisphosphonate therapy. , 2012, Acta medica.

[26]  H. Bang,et al.  The 25(OH)D level needed to maintain a favorable bisphosphonate response is ≥33 ng/ml , 2012, Osteoporosis International.

[27]  I. Starakis,et al.  Recommendations for Diagnosis and Management of Osteoporosis in COPD Men , 2011, ISRN rheumatology.

[28]  W. Fraser,et al.  Low bone mineral density in men with chronic obstructive pulmonary disease , 2011, Respiratory research.

[29]  M. Knorst,et al.  Osteoporosis Prevalence and Associated Factors in Patients With COPD: A Cross-Sectional Study , 2011, Respiratory Care.

[30]  M. Decramer,et al.  COPD, bone metabolism, and osteoporosis. , 2011, Chest.

[31]  A. Anzueto,et al.  Impact of exacerbations on COPD , 2010, European Respiratory Review.

[32]  L. Fabbri,et al.  Efficacy of standard rehabilitation in COPD outpatients with comorbidities , 2010, European Respiratory Journal.

[33]  P. Jones,et al.  Cognitive function in COPD , 2010, European Respiratory Journal.

[34]  Jenny Hall Interpreting qualitative data , 2010 .

[35]  M. Polkey,et al.  The prevalence of quadriceps weakness in COPD and the relationship with disease severity , 2009, European Respiratory Journal.

[36]  C. Jenkins,et al.  Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study. , 2009, Chest.

[37]  H. Orimo [FRAX--Fracture Risk Assessment Tool by WHO]. , 2009, Clinical calcium.

[38]  D. Brooks,et al.  Impairments in balance discriminate fallers from non-fallers in COPD. , 2009, Respiratory medicine.

[39]  J. Oh,et al.  Patients with wrist fractures are less likely to be evaluated and managed for osteoporosis. , 2009, The Journal of bone and joint surgery. American volume.

[40]  E. Wouters,et al.  Current status of research on osteoporosis in COPD: a systematic review , 2009, European Respiratory Journal.

[41]  M. Kochen,et al.  German primary care doctors' awareness of osteoporosis and knowledge of national guidelines. , 2007, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[42]  Peter H Edwards,et al.  Arterial stiffness and osteoporosis in chronic obstructive pulmonary disease. , 2007, American journal of respiratory and critical care medicine.

[43]  A. Giusti,et al.  Secondary Hyperparathyroidism Due to Hypovitaminosis D Affects Bone Mineral Density Response to Alendronate in Elderly Women with Osteoporosis: A Randomized Controlled Trial , 2007, Journal of the American Geriatrics Society.

[44]  V. Backer,et al.  The prevalence of osteoporosis in patients with chronic obstructive pulmonary disease: a cross sectional study. , 2007, Respiratory medicine.

[45]  H. Kroger,et al.  Smoking and fracture risk: a meta-analysis , 2005, Osteoporosis International.

[46]  A. Ionescu,et al.  Associated loss of fat-free mass and bone mineral density in chronic obstructive pulmonary disease. , 2004, American journal of respiratory and critical care medicine.

[47]  O Johnell,et al.  A meta-analysis of previous fracture and subsequent fracture risk. , 2004, Bone.

[48]  M. Vatn,et al.  Vitamin D deficiency, bone mineral density and weight in patients with advanced pulmonary disease , 2004, Journal of internal medicine.

[49]  L. Laslett,et al.  Randomized controlled trial of alendronate in airways disease and low bone mineral density , 2004, Chronic respiratory disease.

[50]  C. Christiansen,et al.  Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study , 2004, Osteoporosis International.

[51]  L. Probyn,et al.  Prevalence of vertebral fractures among patients with chronic obstructive pulmonary disease in Canada , 2003, Osteoporosis International.

[52]  Richard Platt,et al.  Low frequency of treatment of osteoporosis among postmenopausal women following a fracture. , 2003, Archives of internal medicine.

[53]  M. Fulton,et al.  Resistance training prevents vertebral osteoporosis in lung transplant recipients , 2003, Transplantation.

[54]  D. Sin,et al.  The risk of osteoporosis in Caucasian men and women with obstructive airways disease. , 2003, The American journal of medicine.

[55]  C. Cooper,et al.  Epidemiology of fractures in England and Wales. , 2001, Bone.

[56]  R. Burge,et al.  The cost of osteoporotic fractures in the UK: projections for 2000–2020 , 2001 .

[57]  C. Cooper,et al.  Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. , 2000, Rheumatology.

[58]  E. Orwoll,et al.  Alendronate for the treatment of osteoporosis in men. , 2000, The New England journal of medicine.

[59]  W. Bilker,et al.  Treatment of Osteoporosis: Are Physicians Missing an Opportunity?*† , 2000, The Journal of bone and joint surgery. American volume.

[60]  C. Mcevoy,et al.  Association between corticosteroid use and vertebral fractures in older men with chronic obstructive pulmonary disease. , 1998, American journal of respiratory and critical care medicine.

[61]  M. Law,et al.  A meta-analysis of cigarette smoking, bone mineral density and risk of hip fracture: recognition of a major effect , 1997, BMJ.

[62]  S. Cummings,et al.  Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures , 1996, The Lancet.

[63]  E. Shane,et al.  Osteoporosis in lung transplantation candidates with end-stage pulmonary disease. , 1996, The American journal of medicine.